MediFind

Find a Doctor

Tahseen Mozaffar

Regents Of The University Of Claifornia Univ Neursciences
Psychiatry, Neurology
Male
Practicing approx. 31 years

Bio


Tahseen Mozaffar is a Psychiatrist and a Neurologist in Orange, California. He has been an author on 90 peer reviewed articles and participated in 3 clinical trials in the past 15 years. Dr. Mozaffar's top three areas of expertise are Myasthenia Gravis, Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. He is licensed to treat patients in CA.

Contact

Orange, CA 92868, US

Latest Research


Latest Advance
Study
  • Condition: Myasthenia Gravis, Generalized
  • Journal: Neurology
  • Treatment Used: Efgartigimod
  • Number of Patients: 24
  • Published —
In this study, researchers evaluated the safety and effectiveness of efgartigimod for the treatment of generalized myasthenia gravis.
Latest Advance
Study
  • Condition: GNE Myopathy
  • Journal: Neurology
  • Treatment Used: Aceneuramic Acid Extended-Release
  • Number of Patients: 89
  • Published —
This study investigated the safety and effectiveness of aceneuramic acid extended-release to treat patients with GNE myopathy.
Latest Advance
Study
  • Condition: Non-thymomatous myasthenia gravis
  • Journal: The Lancet. Neurology
  • Treatment Used: Thymectomy plus prednisone versus prednisone alone
  • Number of Patients: 111
  • Published —
The study researched the use of thymectomy plus prednisone versus prednisone alone for patients with non-thymomatous myasthenia gravis.
Latest Advance
Study
  • Condition: Patients with Spinal and Bulbar Muscular Atrophy
  • Journal: The Lancet. Neurology
  • Treatment Used: IGF-1 Mimetic
  • Number of Patients: 31
  • Published —
This study assessed safety, tolerability, and preliminary effectiveness of BVS857, an IGF-1 mimetic, in patients with spinal and bulbar muscular atrophy.
Latest Advance
Study
  • Condition: Amyotrophic Lateral Sclerosis (ALS)
  • Journal: Muscle & nerve
  • Treatment Used: Rasagiline
  • Number of Patients: 257
  • Published —
This study evaluated rasagiline, a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects, in patients with amyotrophic lateral sclerosis (ALS).
Latest Advance
Study
  • Condition: Pompe Disease
  • Journal: Molecular therapy : the journal of the American Society of Gene Therapy
  • Treatment Used: Duvoglustat HCl
  • Number of Patients: 25
  • Published —
This study evaluated the effect of single oral doses of 50 mg, 100 mg, 250 mg, or 600 mg duvoglustat HCl on the pharmacokinetics and tissue levels of intravenously infused alglucosidase alfa (AA ; 20 mg/kg) in patients with Pompe disease (neuromuscular disorder).

Clinical Trials


Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 125
  • Start Date: February 12, 2018
Topiramate as a Disease Modifying Therapy for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Clinical Trial
Other
  • Status: Recruiting
  • Participants: 50
  • Start Date: February 7, 2017
Fluid Biomarkers With Deep Phenotyping in Patients With ALS

All Publications
View All


Publication
Study
  • Journal: Journal of clinical neuromuscular disease
  • Published —
Attitudes Toward Noninterventional Observational Studies in US and Australian Patients With Sporadic Inclusion Body Myositis.
Publication
Study
  • Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
  • Published —
Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis.

Contact

Orange, CA 92868, US

Affiliations

  • University Of California Irvine Med Center

Credentials

  • Licenses
    Psychiatry & Neurology in CA
  • Board Certifications
    Neurology

Insurance

Contact them to find out if they accept your insurance plan.